Questions
123456789
Reading 1/2:
9. Sweden has also begun trialing a scheme that offers five antibiotic manufacturers minimum guaranteed payments for their drugs. This is designed to encourage firms to make existing antibiotics available in Sweden, because the country uses less antibiotics per head than similar high-income countries.
1) Which of the following statements is TRUE about the use of Zavicefta and Fetcroja?
A. They are not the first to be used for treating infections.
B. They are both created by combining two types of drugs.
C. They are used for treating the same conditions.D. They are always available on prescription.
2) Which of the following is a strong inference from the following sentence?
"NHS England's subscription model is the first designed explicitly to reimburse firms with an amount that reflects an antibiotic's overall value to a health service, even if it is kept as a medicine of last resort and not used very much."
A.Antibiotic value to the health service is the focus of the reimbursement provided by the subscription model.
B. The subscription model aims to encourage pharmaceutical firms to develop new antibiotics.. The subscription model only focuses on the financial gain of pharmaceutical companies.
C D. Pharmaceutical firms will receive payments based on the quantity of antibiotics sold.
Next Reading
3) What is one of the greatest threats associated with antibiotic-resistant bacteria?
A. The number of effective antibiotics has increased.
B. There is a decrease in the need for medical care.C. The number of curable infections has decreased.
D. It's more difficult, even impossible, to cure some diseases.
4) Why is the field of antibiotics unable to generate profit for pharmaceutical companies?
A. limited usage of new antibiotics
B. lack of research and development C. excessive government regulations
D. low demand for antibiotics
5) Which of the following statements is TRUE about the schemes of the US Senate and Sweden?
A. Both schemes are planned to launch at the same time.
B. Both schemes encourage antibiotic manufacturers to produce more drugs.
C. The criteria for payment of the two schemes are completely different.
OD
Next Question
